212Pb-DOTAM-GRPR1 / Orano - LARVOL DELTA

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors (clinicaltrials.gov) - P1 | N=55 | Recruiting | Sponsor: Orano Med LLC | N=30 ➔ 55 | Trial completion date: Jan 2025 ➔ Aug 2027 | Trial primary completion date: Aug 2024 ➔ Aug 2026

Enrollment change • Trial completion date • Trial primary completion date • Breast Cancer • Castration-Resistant Prostate Cancer • Cervical Cancer • Colon Cancer • Colorectal Cancer • Cutaneous Melanoma • Genito-urinary Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Prostate Cancer • Solid Tumor • GRP-10 • HER-2

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Orano Med LLC | N=50 ➔ 30

Enrollment change • Metastases • Breast Cancer • Cervical Cancer • Colon Cancer • Colorectal Cancer • Cutaneous Melanoma • Gastrointestinal Cancer • Genito-urinary Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Prostate Cancer • Solid Tumor • GRP-10 • HER-2

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors (clinicaltrials.gov) - P1 | N=50 | Recruiting | Sponsor: Orano Med LLC | Not yet recruiting ➔ Recruiting | Initiation date: May 2022 ➔ Dec 2022

Enrollment open • Metastases • Trial initiation date • Breast Cancer • Cervical Cancer • Colon Cancer • Colorectal Cancer • Cutaneous Melanoma • Gastrointestinal Cancer • Genito-urinary Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Prostate Cancer • Solid Tumor • GRP-10 • HER-2

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors (clinicaltrials.gov) - P1 | N=50 | Not yet recruiting | Sponsor: Orano Med LLC

New P1 trial • Breast Cancer • Cervical Cancer • Colon Cancer • Colorectal Cancer • Cutaneous Melanoma • Gastrointestinal Cancer • Genito-urinary Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Prostate Cancer • Solid Tumor • GRP-10 • HER-2